Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. VEGF-C as a putative therapeutic target in cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE: Glioblastoma (GBM) ranks among the deadliest solid cancers worldwide and its prognosis has remained dismal, despite the use of aggressive chemo-irradiation treatment regimens. Limited drug delivery into the brain parenchyma and frequent resistance to currently available therapies are problems that call for a prompt development of novel therapeutic strategies. While only displaying modest efficacies as mono-therapy in pre-clinical settings, histone deacetylase inhibitors (HDACi) have shown promising sensitizing effects to a number of cytotoxic agents. Here, we sought to investigate the sensitizing effect of the HDACi trichostatin A (TSA) to the alkylating agent lomustine (CCNU), which is used in the clinic for the treatment of GBM.

METHODS: Twelve primary GBM cell cultures grown as neurospheres were used in this study, as well as one established GBM-derived cell line (U87 MG). Histone deacetylase (HDAC) expression levels were determined using quantitative real-time PCR and Western blotting. The efficacy of either CCNU alone or its combination with TSA was assessed using various assays, i.e., cell viability assays (MTT), cell cycle assays (flow cytometry, FACS), double-strand DNA break (DSB) quantification assays (microscopy/immunofluorescence) and expression profiling assays of proteins involved in apoptosis and cell stress (Western blotting and protein array).

RESULTS: We found that the HDAC1, 3 and 6 expression levels were significantly increased in GBM samples compared to non-neoplastic brain control samples. Additionally, we found that pre-treatment of GBM cells with TSA resulted in an enhancement of their sensitivity to CCNU, possibly via the accumulation of DSBs, decreased cell proliferation and viability rates, and an increased apoptotic rate.

CONCLUSION: From our data we conclude that the combined administration of TSA and CCNU eradicates GBM cells with a higher efficacy than either drug alone, thereby opening a novel avenue for the treatment of GBM.

Original languageEnglish
JournalCellular oncology (Dordrecht)
Volume40
Issue number1
Pages (from-to)21–32
Number of pages12
ISSN2211-3428
DOIs
Publication statusPublished - Feb 2017

ID: 49459966